Last reviewed · How we verify
Oral anticoagulation therapy
Oral anticoagulation therapy prevents blood clot formation by inhibiting coagulation cascade factors, reducing thromboembolism risk.
Oral anticoagulation therapy prevents blood clot formation by inhibiting coagulation cascade factors, reducing thromboembolism risk. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism prevention and treatment, Mechanical heart valve thromboprophylaxis.
At a glance
| Generic name | Oral anticoagulation therapy |
|---|---|
| Also known as | warfarin or rivaroxaban, Warfarin/Coumadin, New oral anticoagulants (NOACs): dabigatran, rivaroxaban, apixaban |
| Sponsor | China National Center for Cardiovascular Diseases |
| Drug class | Oral anticoagulant |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Oral anticoagulants work through multiple mechanisms depending on the specific agent—vitamin K antagonists inhibit factors II, VII, IX, and X, while direct oral anticoagulants (DOACs) directly inhibit factor Xa or thrombin (factor IIa). These mechanisms prevent the formation of fibrin clots and reduce the risk of thrombotic events in conditions like atrial fibrillation and venous thromboembolism.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention
- Mechanical heart valve thromboprophylaxis
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Dyspepsia
- Liver enzyme elevation
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation
- Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia (PHASE4)
- Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF (NA)
- Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (NA)
- A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF (PHASE4)
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: